A Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
Price : $35 *
At a glance
- Drugs Pimasertib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors EMD Serono
- 24 Aug 2014 Status changed from active, no longer recruiting to completed as reported by M.D. Anderson Cancer Center record.
- 04 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 02 Dec 2013 New trial record